AAV9 Potency Assays: IND-Enabling Analytics for CNS and Systemic Gene Therapies
A well-defined potency assay is a foundational component of any successful Investigational New Drug (IND) submission for an AAV9-based therapeutic. For programs targeting neurological or systemic disorders, this assay provides regulatory bodies with key evidence of the product’s biological activity and consistency between manufacturing lots. The assay must quantitatively measure biological function, moving beyond simple confirmation of the vector’s presence.
The development of a suitable potency assay is directly influenced by upstream decisions in vector production. The selection of a manufacturing platform has measurable consequences for vector efficacy. For instance, comparative analysis of AAV vectors produced in HEK293 versus Sf9/baculovirus systems reveals significant differences in capsid integrity and subsequent in vivo potency (PMID: 37597192). An IND-enabling analytical strategy must be robust enough to detect these functional differences, ensuring that the material used in pivotal preclinical studies is representative of the intended clinical product.
A phase-appropriate approach is necessary for developing these complex analytical methods under GLP conditions. The strategy often involves a matrix of assays that collectively define the product’s potency:
-
Vector Integrity Assays: Confirming the proper ratio of full-to-empty capsids and the integrity of the encapsidated genome.
-
Transgene Expression Assays: Using in vitro cell-based models to quantify the expression of the therapeutic protein or functional RNA.
-
Functional Assays: Measuring a biological activity that is directly related to the therapeutic’s mechanism of action in a relevant biological system.
For gene editing applications delivered via AAV9, confirming on-target activity is another layer of potency characterization. Advanced sequencing assays can identify genome-wide editing sites in biological samples from in vivo models, providing definitive evidence of the vector’s intended biological effect (PMID: 32183699). This level of deep characterization provides a higher degree of confidence for regulatory submissions. Our approach to capsid engineering and preclinical safety profiling is detailed further in our technical webinars.
Our teams possess deep expertise in this area, with one partner noting our “Vast knowledge in all aspects of vector production and analytics.” This specialized analytical capability is integrated within our broader Vector | CMC | Analytics Services, ensuring that the potency assay strategy aligns with the entire manufacturing and preclinical testing program.
